News
HKMPF
19.07
NaN%
--
Berenberg Bank Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 13h ago
Hikma Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
TipRanks · 3d ago
Barclays upgrades Hikma Pharmaceuticals (HIK) to a Hold
TipRanks · 3d ago
Weekly Report: what happened at HKMPF last week (0831-0904)?
Weekly Report · 4d ago
Weekly Report: what happened at HKMPF last week (0824-0828)?
Weekly Report · 08/31 09:12
Hikma completes $250m share buyback, reshaping capital structure
TipRanks · 08/28 06:13
Hikma Executives Restructure Pledges Over 2 Million Shares via Darhold
TipRanks · 08/24 14:07
Hikma Advances $250m Share Buyback, Tightens Free Float
TipRanks · 08/24 09:57
Weekly Report: what happened at HKMPF last week (0817-0821)?
Weekly Report · 08/24 09:12
Hikma steps up $250m buyback with latest share repurchases
TipRanks · 08/17 12:07
Weekly Report: what happened at HKMPF last week (0810-0814)?
Weekly Report · 08/17 09:12
Citi Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 08/12 07:35
Hikma price target raised to 2,100 GBp from 1,800 GBp at Berenberg
TipRanks · 08/11 16:05
Hikma Director Tobias Hestler Boosts Stake with £123,600 Share Purchase
TipRanks · 08/11 09:53
Hikma Pharmaceuticals (HIK) Gets a Buy from Berenberg Bank
TipRanks · 08/11 09:16
Weekly Report: what happened at HKMPF last week (0803-0807)?
Weekly Report · 08/10 09:11
Hikma Advances $250m Buyback, Cuts Share Count and Voting Rights
TipRanks · 08/10 09:07
Hikma Pharmaceuticals Balances Strong H1 With Cautious Outlook
TipRanks · 08/07 00:12
Hikma strengthens board with appointment of former Haleon CFO Tobias Hestler
TipRanks · 08/06 06:17
Hikma lifts profit and R&D spend as it reaffirms 2026 outlook
TipRanks · 08/06 06:09
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.